News & Updates

Renal impairment, race affect maintenance warfarin dosing in Asian patients

08 Jun 2024 by

Race and renal function both influence maintenance warfarin dosing in a multi-ethnic Southeast Asian population, suggests a study in Singapore. Specifically, impaired renal function is associated with lower warfarin maintenance doses, while South Asians may require a larger dose than Chinese and Malays.

Renal impairment, race affect maintenance warfarin dosing in Asian patients

08 Jun 2024

Lidocaine-filled dilators may minimize pain during IUD removal

08 Jun 2024

Infusing lidocaine into a disposable injectable cervical dilator helps reduce pain during the removal of an intrauterine device (IUD), especially when intrauterine manipulations are needed, according to a study.

Lidocaine-filled dilators may minimize pain during IUD removal

08 Jun 2024

Does adjuvant chemotherapy improve survival in stage II colon cancer?

07 Jun 2024

In patients with stage II colon cancer, individuals with a right-sided colon cancer (RSCC) appear to have a better prognosis than those with a left-sided colon cancer (LSCC), reveals a recent study. Additionally, adjuvant chemotherapy (ACT) falls short of improving cause-specific survival (CSS) in patients with either RSCC or LSCC.

Does adjuvant chemotherapy improve survival in stage II colon cancer?

07 Jun 2024

ART discontinuation tied to toxicity, disease progression in mCRPC patients

07 Jun 2024

Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.

ART discontinuation tied to toxicity, disease progression in mCRPC patients

07 Jun 2024

Atrasentan a new player in the IgAN treatment field?

07 Jun 2024 by

In the prespecified interim analysis of the phase III ALIGN study, the investigational drug atrasentan shows promising signals when added to standard supportive care with a renin-angiotensin system (RAS) inhibitor in patients with IgA nephropathy (IgAN).

Atrasentan a new player in the IgAN treatment field?

07 Jun 2024

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

07 Jun 2024

Glucose-lowering drugs such as the glucagon-like peptide-1 receptor agonist (GLP-1-RA), sodium-glucose cotransporter 2 inhibitor (SGLT2i), and dipeptidyl peptidase-4 inhibitor (DPP-4i) work better and are more cost-effective than sulfonylureas and glinides (SU) as second-line treatment for type 2 diabetes (T2D), according to a population-based retrospective cohort study.

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

07 Jun 2024

CD38 monoclonal antibody shows promise in kidney transplant rejection

06 Jun 2024

In the treatment of kidney transplant recipients with antibody-mediated rejection, the CD38 monoclonal antibody felzartamab demonstrates acceptable safety and side-effect profiles as well as potential therapeutic benefit, according to a phase II trial.

CD38 monoclonal antibody shows promise in kidney transplant rejection

06 Jun 2024

1-day on par with 5-day octreotide in preventing bleeding, death from esophageal varices

05 Jun 2024 by

A 1-day regimen of octreotide infusion, along with endoscopic therapy for variceal bleeding, does not appear to be inferior to the standard 5-day regimen in the prevention of rebleeding and all-cause mortality at 6 weeks, according to the preliminary results of a study.

1-day on par with 5-day octreotide in preventing bleeding, death from esophageal varices

05 Jun 2024

Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19

05 Jun 2024 by

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19

05 Jun 2024

PAD guideline updates clinicians should know

05 Jun 2024 by

The American College of Cardiology and the American Heart Association (ACC/AHA), in collaboration with nine other societies, have released the 2024 guideline for managing peripheral artery disease (PAD), with new recommendations to guide practice.

PAD guideline updates clinicians should know

05 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Renal impairment, race affect maintenance warfarin dosing in Asian patients

Renal impairment, race affect maintenance warfarin dosing in Asian patients

Lidocaine-filled dilators may minimize pain during IUD removal

Lidocaine-filled dilators may minimize pain during IUD removal

Does adjuvant chemotherapy improve survival in stage II colon cancer?

Does adjuvant chemotherapy improve survival in stage II colon cancer?

ART discontinuation tied to toxicity, disease progression in mCRPC patients

ART discontinuation tied to toxicity, disease progression in mCRPC patients

Atrasentan a new player in the IgAN treatment field?

Atrasentan a new player in the IgAN treatment field?

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

Newer glucose-lowering drugs best sulfonylureas, glinides in second-line treatment of T2D

CD38 monoclonal antibody shows promise in kidney transplant rejection

CD38 monoclonal antibody shows promise in kidney transplant rejection

1-day on par with 5-day octreotide in preventing bleeding, death from esophageal varices

1-day on par with 5-day octreotide in preventing bleeding, death from esophageal varices

Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19

Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19

PAD guideline updates clinicians should know

PAD guideline updates clinicians should know